Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
VERAthis companyVera Therapeutics, Inc.	$29.92	-10.87×	5.38×	0×	-10.2×	-86.6%	0.0%	0.0%	0.0%	-49.6%	-46.3%	-7.4%	0.13×	0.95×	-41.89×	13.64×	0.0%	1	6.48	1	C-
ACRSAclaris Therapeutics, Inc.	$4.22	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
ALMSAlumis Inc.	$6.39	-4.21×	27.54×	345.07×	-33.2×	-85.0%	85.5%	-1776.3%	-1011.7%	-80.8%	-120.2%	-4.5%	0.12×	0.21×	0×	4.34×	0.0%	2	0.06	1	C-
ANABAnaptysBio, Inc.	$47.82	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
ARQTArcutis Biotherapeutics, Inc.	$25.74	-223.38×	19.5×	9.82×	2,055.19×	-632.3%	90.2%	-3.3%	-4.3%	-8.5%	-4.0%	-0.2%	0.03×	-20.58×	-1.01×	3.17×	0.0%	7	7.53	2	C+
BHVNBiohaven Ltd.	$15.18	-1.65×	23.33×	0×	-1.75×	-103.9%	0.0%	0.0%	0.0%	-1418.8%	-218.4%	-50.2%	5.47×	-0.08×	0×	3.18×	0.0%	3	-15.51	2	C
Peer median	—	-5.68×	23.33×	9.82×	-1.75×	-122.2%	85.5%	-3.3%	-5.6%	-63.0%	-57.7%	-4.5%	0.12×	-0.08×	0×	4.34×	0.0%	3	0.06	2	—